Natural History Study of Infants and Children With SCN1A-positive Dravet Syndrome

Open to people ages 6 months to 60 months

• Confirmed SCN1A mutation.
• Normal development prior to onset of first seizure as defined by the Centers for Disease -Control and Prevention (CDC 2019).
• Onset of seizures between age 3 and 15 months, inclusive.

• Copy number variant of SCN1A, including SCN1A microdeletion, if affecting other genes.
• SCN1A mutation present on both alleles. Known pathogenic or clinically suspected mutation in a seizure-associated gene besides SCN1A.
• Confirmed mutation in a gene besides SCN1A, as determined by an Independent Adjudication Committee, that is known to increase the severity of the seizure phenotype.
• Participant has a known gain-of-function genetic mutation, as defined by functional studies, including p.Thr226Met.
• History of notable developmental deficit that was evident prior to seizure onset.
• Known central nervous system structural abnormality as found on magnetic resonance imaging or computed tomography scan of brain.
• Participant is currently taking or has taken for 6 or more consecutive weeks anti-seizure medications (ASMs) at a therapeutic dose that are contraindicated in SCN1A-positive Dravet Syndrome, including sodium channel blockers.
• Known concomitant genetic mutation or clinical comorbidity that potentially confounds typical Dravet phenotype.